ALLK
Allakos
–
Index: NASDAQ; Sector: Healthcare; Industry: Biotechnology & Drugs;
Marketcap: 3.91B; Volume: 123.28K; AvgVol 3m: 193.55K; Beta: –;
Cost estimate:
P/E: –; EPS: -2.35; EPS growth quarter/prev quarter: -82.00%;
EPS growth this year: -87.00%; EPS growth past 5 years: ;
EPS ttm: -2.35;
P/S: ; P/B: 9.15; P/Cashflow: 9.10; P/FCF: ;
Sales: –; Sales growth quarter/prev quarter: ; Sales growth past 5 years: ;
Profitability:
Gross Margin: ; Profit Margin: ; Operating Margin: ;
ROA – return on assets: -22.40%; ROE – return on equity: -23.50%; LT Debt/Equity: 0.00; Total Debt/Equity: 0.00;
Dividend: –; Dividend Yield (%): –;
Insider Ownership: 10.90%; Insider Transactions:-30.21%;
Institutional Ownership: ; Institutional Transactions: ;
Data update: 07.10.2020.